Showing results (71-80 of 108) with videos related to
Sort By:
Pageof 11
Lancet (London, England)|October 9, 2019
Durvalumab plus platinum-etoposide versus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trialLuis Paz-Ares, Mikhail Dvorkin, Yuanbin Chen, et al.Journal for Immunotherapy of Cancer|May 8, 2021
Tumor mutational burden assessment in non-small-cell lung cancer samples: results from the TMB<sup>2</sup> harmonization project comparing three NGS panelsJavier Ramos-Paradas, Susana Hernández-Prieto, David Lora, et al.Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|May 20, 2018
Updated Efficacy Analysis Including Secondary Population Results for OAK: A Randomized Phase III Study of Atezolizumab versus Docetaxel in Patients with Previously Treated Advanced Non-Small Cell Lung CancerLouis Fehrenbacher, Joachim von Pawel, Keunchil Park, et al.NPJ Precision Oncology|February 26, 2024
Genomic landscape of liquid biopsy mutations in TP53 and DNA damage genes in cancer patientsDamien Vasseur, Ahmadreza Arbab, Fabiola Giudici, et al.Drugs & Aging|May 15, 2025
Age Does not Affect the Efficacy of Antibody Drug Conjugates, But is Associated with High-Grade Adverse Events in Patients with Cancer Enrolled in Early Phase Clinical TrialsAna Vaz Ferreira, Matthieu Delaye, Arnaud Pages, et al.Critical Reviews in Oncology/Hematology|November 25, 2023
Antibody drug conjugates in older patients: State of the artLayal Rached, Arthur Geraud, Maxime Frelaut, et al.Lung Cancer (Amsterdam, Netherlands)|August 27, 2019
Oral vinorelbine versus etoposide with cisplatin and chemo-radiation as treatment in patients with stage III non-small cell lung cancer: A randomized phase II (RENO study)Dolores Isla, Ramón De Las Peñas, Amelia Insa, et al.The Lancet. Oncology|December 7, 2020
Durvalumab, with or without tremelimumab, plus platinum-etoposide versus platinum-etoposide alone in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): updated results from a randomised, controlled, open-label, phase 3 trialJonathan W Goldman, Mikhail Dvorkin, Yuanbin Chen, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 5, 2020
PD-1 Blockade in Anaplastic Thyroid CarcinomaJaume Capdevila, Lori J Wirth, Thomas Ernst, et al.European Journal of Cancer (Oxford, England : 1990)|July 10, 2024
Capmatinib plus nazartinib in patients with EGFR-mutated non-small cell lung cancerEnriqueta Felip, Giulio Metro, Ross A Soo, et al.Pageof 11